Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 220

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 220
---
) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG AZSA LLC

Tokyo, Japan

F-4

TAKEDA PHARMACEUTICAL COMPANY LIMITED AND ITS SUBSIDIARIES

Consolidated Statements of Profit or Loss for the Year Ended March 31,

                                                                                        Note      2023                                                         2024                         2025                        
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                                                  JPY (millions, except per share data)                                                                                 
  Revenue                                                                                  4      ¥                                             4,027,478      ¥             4,263,762      ¥                4,581,551  
  Cost of sales                                                                                                                              ( 1,244,072)                 ( 1,426,678)                    ( 1,580,217)  
  Selling, general and administrative expenses                                                                                                 ( 997,309)                 ( 1,053,819)                    ( 1,104,766)  
  Research and development expenses                                                                                                            ( 633,325)                   ( 729,924)                      ( 730,227)  
  Amortization and impairment losses on intangible assets associated with products        12                                                   ( 542,443)                   ( 652,117)                      ( 643,233)  
  Other operating income                                                                   5                                                       25,424                       19,379                          26,212  
  Other operating expenses                                                                 5                                                   ( 145,247)                   ( 206,527)                      ( 206,733)  
  Operating profit                                                                                                                                490,505                      214,075                         342,586  
  Finance income                                                                           6                                                       62,913